Zdrowie i gospodarka · 29/09/2010

FDA Releases Draft Guidance on Safety Reporting Requirements for INDs and Bioavailability Studies

The Food and Drug Administration (FDA) has made available a draft guidance document aimed at helping industry sponsors and investigators comply with new safety reporting requirements for Investigational New Drug Applications and bioavailability/bioequivalence studies, as outlined in the recently published final rule.